ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment

ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFD...

ViGenCell, NK/T cell lymphoma treatment ‘VT-EBV-N’ designated as orphan drug in Europe

ViGenCell, a company specializing in immune cell therapy, announced on the 19th that its NK/T cell lymphoma treatment "VT-EBV-N" has been designated...

VaxCell-Bio applies for approval of anti-cancer drug for dogs

South Korea’s VaxCell Biotherapeutics Co. (VaxCell-Bio) on Tuesday announced its application for approval for Vaxleukin-15, an anti-cancer dru...

Verismo's CAR-T therapy designated fast-track status by FDA

Verismo Therapeutics, a US affiliate of South Korean pharmaceutical firm HLB Co., has received fast-track designation from the US Food and Drug Admi...

GC Cell's AB-101 NK therapy achieves FDA fast-track status

South Korea's bio firm GC Cell announced on Wednesday that its US affiliate Artiva Biotherapeutics has received fast-track designation from the US F...